Christopher Missling
Chief Executive Officer at ANAVEX LIFE SCIENCES CORP.
Net worth: 4 M $ as of 2024-04-29
Profile
Christopher U.
Missling is currently the President, CEO, Secretary & Director at Anavex Life Sciences Corp.
He previously held positions as the Chief Financial Officer at ImmunoGen, Inc., CFO & Senior Vice President-Strategic Operations at Curis, Inc., Head-Financial Planning at Aventis, Inc., and Head-Healthcare Investment Banking at Brimberg & Co. He has a graduate and doctorate degree from Ludwig-Maximilians-Universität München, an MBA from WHU-Otto Beisheim School of Management, and another MBA from Kellogg School of Management.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2024-03-27 | 1,250,210 ( 1.52% ) | 4 M $ | 2024-04-29 |
Christopher Missling active positions
Companies | Position | Start |
---|---|---|
ANAVEX LIFE SCIENCES CORP. | Chief Executive Officer | 2013-07-04 |
Former positions of Christopher Missling
Companies | Position | End |
---|---|---|
Aventis, Inc. | Corporate Officer/Principal | - |
IMMUNOGEN, INC. | Director of Finance/CFO | - |
Brimberg & Co.
Brimberg & Co. Investment Banks/BrokersFinance Brimberg & Co. LP is a broker/dealer headquartered in New York City. They provide a full array of trading and execution services for their clients. They do not provide any internal research. | Corporate Officer/Principal | - |
CURIS, INC. | Director of Finance/CFO | - |
Training of Christopher Missling
Ludwig-Maximilians-Universität München | Doctorate Degree |
Kellogg School of Management | Masters Business Admin |
WHU-Otto Beisheim School of Management | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
CURIS, INC. | Health Technology |
ANAVEX LIFE SCIENCES CORP. | Health Technology |
Private companies | 3 |
---|---|
ImmunoGen, Inc.
ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA. | Health Technology |
Brimberg & Co.
Brimberg & Co. Investment Banks/BrokersFinance Brimberg & Co. LP is a broker/dealer headquartered in New York City. They provide a full array of trading and execution services for their clients. They do not provide any internal research. | Finance |
Aventis, Inc. |
- Stock Market
- Insiders
- Christopher Missling